ANGELA JOHNSEN: Open Payments
NPI 1295970291 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$753 in 41 payments from 12 companies in 2025. Trend: 2023 $150 · 2024 $22 · 2025 $753
Food & beverage: $753
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $194 |
| ABBVIE INC. | 11 | $170 |
| Teva Pharmaceuticals USA, Inc. | 3 | $76 |
| Axsome Therapeutics, Inc. | 4 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
| Alkermes, Inc. | 2 | $45 |
| Neurocrine BioSciences, Inc. | 2 | $35 |
| Lundbeck LLC | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: REXULTI, VRAYLAR, Auvelity, CAPLYTA, AUSTEDO XR, ARISTADA, INGREZZA, FANAPT.
Industry payments across NE — which companies pay providers there.
